GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo Inc (OTCPK:NDOI) » Definitions » Notes Receivable

Endo (NDOI) Notes Receivable : $0 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Endo Notes Receivable?

Endo's Notes Receivable for the quarter that ended in Dec. 2024 was $0 Mil.


Endo Notes Receivable Historical Data

The historical data trend for Endo's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endo Notes Receivable Chart

Endo Annual Data
Trend Dec22 Dec23 Dec24
Notes Receivable
- - -

Endo Quarterly Data
Jun23 Sep23 Dec23 Apr24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial - - - - -

Endo Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Endo Notes Receivable Related Terms

Thank you for viewing the detailed overview of Endo's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Endo Business Description

Traded in Other Exchanges
N/A
Address
9 Great Valley Parkway, Malvern, PA, USA, 19355
Endo Inc is a diversified pharmaceutical company. It has four reportable business segments: (1) Branded Pharmaceuticals, (2) Sterile Injectables, (3) Generic Pharmaceuticals and (4) International Pharmaceuticals. Branded Pharmaceuticals segment includes a variety of branded products in the therapeutic areas of urology, orthopedics, etc. Sterile Injectables segment consists of branded sterile injectable products such as ADRENALIN, VASOSTRICT and APLISOL, among others. Generic Pharmaceuticals segment includes a product portfolio including patches, solid oral extended-release products, etc. Key revenue is generated from International Pharmaceuticals segment includes a variety of specialty pharmaceutical products, including OTC products, sold outside the U.S.